JKB 122

Drug Profile

JKB 122

Latest Information Update: 04 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jenken Biosciences
  • Developer Jenken Biosciences; TaiwanJ Pharmaceuticals
  • Class Hepatoprotectants
  • Mechanism of Action Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease; Hepatitis; Hepatitis C; Non-alcoholic fatty liver disease

Most Recent Events

  • 01 Mar 2016 Phase-II clinical trials in Crohn's disease, Hepatitis and Non-alcoholic fatty liver disease in Taiwan (PO)
  • 01 Feb 2016 Phase-II clinical trials in Hepatitis (autoimmune hepatitis) in USA (PO) (NCT02556372)
  • 05 Nov 2015 US FDA approves IND application for JKB 122 in Hepatitis (Treatment-resistant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top